Friday, September 5, 2025

DiagnaMed Anticipates CERVAI Commercial Launch In Q4 2023

FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.

DiagnaMed Holdings (CSE: DMED) is expected to begin the deployment of its brain age estimation tool known as CERVAI to third party sites in the fourth quarter of 2023.

“We are excited about the development progress we have made with CERVAI™, our proprietary generative AI brain health platform, and we expect to have our initial commercial launch for clinic or at-home use in Q4-2023,” commented CEO Fabio Chianelli in an updated issued this morning by the company.

The tool, developed in combination with Drexel University under license, consists of an EEG headset that uses machine learning techniques and data recording protocols to evaluate overall brain health. The assessment tool generates both self-report and clinician-observed measures to output a patient risk score and provide actionable points for improvement. The tech incorporates the use of OpenAI’s ChatGPT to develop personalized treatment plans and interventions for mental health and neurodegenerative conditions.

READ: DiagnaMed Launches Dr. GenAI, A Generative AI Medical Chatbot

The first phase of the development of the tool is said to have been completed, which included laboratory-based testing of indiviudals. The model is said to have accurately predicated chronological ages with “a medium-to-strong statistical effect-size.” The final phase of development will now see the EEG headsets used at home by individuals to test the tech in various settings.

With commercialization expected to begin in the fourth quarter, the company intends to tackle the target markets of health and wellness clinics, fitness clubs, physician offices, and sports clubs among other targets.

“We expect CERVAI™ to be a practical tool for the millions of people with mental illness and neurodegenerative diseases,” continued Chianelli.

Diagnamed Holdings last traded at $0.075 on the CSE.


FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of DiagnaMed Holdings. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

ESGold Outlines $24.3 Million NPV For Tailings Reprocessing Project

First Majestic Encounters 711 g/t Silver Equivalent Over 8.0 Metres In Ongoing Exploration At Los Gatos

Related News

DiagnaMed Opens Enrollment For Healthcare Provider Network For Brain Health Platform

DiagnaMed Holdings (CSE: DMED) is moving forward with the commercialization of CERVAI, its brain health...
Tuesday, October 3, 2023, 09:08:43 AM

DiagnaMed Enhances CERVAI Brain Health Platform Commercialization Efforts In Canada

DiagnaMed Holdings (CSE: DMED) continues to progress with the commercialization of its CERVAI Brain Health...
Tuesday, March 12, 2024, 09:19:18 AM

DiagnaMed Looks To Obtain Approval For Brain Age Clinical Tool In Q4

DiagnaMed Holdings (CSE: DMED) is moving towards obtaining regulatory approval for its Brain Age clinical...

Tuesday, January 31, 2023, 10:13:10 AM

DiagnaMed Begins Test Launch of CERVAI

A test launch is currently underway for CERVAI, which has been deemed as a world-first...
Wednesday, February 28, 2024, 10:25:10 AM

DiagnaMed Launches Dr. GenAI, A Generative AI Medical Chatbot

DiagnaMed Holdings (CSE: DMED) has launched its third generative AI product to the marketplace....
Thursday, June 15, 2023, 09:05:58 AM